Corvus Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Corvus Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$34.31 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Corvus Pharmaceuticals Inc had its IPO on 2016-03-23 under the ticker symbol CRVS.

The company operates in the Healthcare sector and Biotechnology industry. Corvus Pharmaceuticals Inc has a staff strength of 28 employees.

Stock update

Shares of Corvus Pharmaceuticals Inc opened at $0.74 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $0.69 - $0.75, and closed at $0.74.

This is a -0.27% slip from the previous day's closing price.

A total volume of 154,100 shares were traded at the close of the day’s session.

In the last one week, shares of Corvus Pharmaceuticals Inc have increased by +3.52%.

Corvus Pharmaceuticals Inc's Key Ratios

Corvus Pharmaceuticals Inc has a market cap of $34.31 million, indicating a price to book ratio of 0.576 and a price to sales ratio of 0.

In the last 12-months Corvus Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32763000. The EBITDA ratio measures Corvus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Corvus Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -20.74% with a return of equity of -47.96%.

In Q3, Corvus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Corvus Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Corvus Pharmaceuticals Inc’s profitability.

Corvus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.2654. Its price to sales ratio in the trailing 12-months stood at 0.

Corvus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$80.35 million
Total Liabilities
$13.98 million
Operating Cash Flow
$3.04 million
Capital Expenditure
Dividend Payout Ratio

Corvus Pharmaceuticals Inc ended 2023 with $80.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $80.35 million while shareholder equity stood at $64.68 million.

Corvus Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $13.98 million in other current liabilities, 5000.00 in common stock, $-297872000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.59 million and cash and short-term investments were $49.62 million. The company’s total short-term debt was $1,181,000 while long-term debt stood at $0.

Corvus Pharmaceuticals Inc’s total current assets stands at $51.27 million while long-term investments were $25.91 million and short-term investments were $25.03 million. Its net receivables were $534000.00 compared to accounts payable of $4.23 million and inventory worth $0.

In 2023, Corvus Pharmaceuticals Inc's operating cash flow was $3.04 million while its capital expenditure stood at $265000.

Comparatively, Corvus Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Corvus Pharmaceuticals Inc stock is currently trading at $0.74 per share. It touched a 52-week high of $2.11 and a 52-week low of $2.11. Analysts tracking the stock have a 12-month average target price of $2.83.

Its 50-day moving average was $0.79 and 200-day moving average was $0.9 The short ratio stood at 2.17 indicating a short percent outstanding of 0%.

Around 397.9% of the company’s stock are held by insiders while 4597.7% are held by institutions.

Frequently Asked Questions About Corvus Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Corvus Pharmaceuticals Inc is CRVS

The IPO of Corvus Pharmaceuticals Inc took place on 2016-03-23

Similar Industry Stocks (Biotechnology)

Last Price
Gevo Inc (GEVO)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.


863 Mitten Road, Burlingame, CA, United States, 94010